Quantcast
Channel: Medical Xpress news tagged with:aortic valve
Viewing all 102 articles
Browse latest View live

Results of the COREVALVE EXTREME RISK trial presented

0
0
In a clinical trial, a self-expanding transcatheter aortic valve met the key performance objective of reducing death and stroke in patients with severe aortic stenosis at "extreme risk" for surgery.Results of the COREVALVE EXTREME RISK trial were presented today at the 25th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. Sponsored by the Cardiovascular Research Foundation (CRF), TCT is the world's premier educational meeting specializing in interventional cardiovascular medicine.

SAPIEN 3 improves 30-day outcomes for major endpoints

0
0
The SAPIEN 3 heart valve demonstrated lower death, stroke and paravalvular leak rates than earlier generation devices in patients at high risk for surgery and showed encouraging results in intermediate-risk patients, according to research presented at the American College of Cardiology's 64th Annual Scientific Session.

FDA expands approval for 'valve in valve' aortic replacement

0
0
(HealthDay)—The U.S. Food and Drug Administration said Tuesday that use of the CoreValve "valve-in-valve" aortic replacement has been expanded to include people at extreme risk for serious complications of traditional open-heart surgery.

TAVI, safe and effective as surgical valves at two years in lower risk patients

0
0
Two year outcomes in a study comparing implantation of transcatheter and surgical bioprosthestic aortic valves shows that the less invasive procedure is safe and effective, and comparable to the gold standard, surgical valve replacement, in patients whose operational risk was lower than that of patients studied in the pivotal randomized trials for these new devices.

New data clarify leaflet thickening in TAVI and surgical aortic prostheses

0
0
New data released today at EuroPCR 2015 suggest that thickening of the valve leaflets following implantation of a transcatheter or surgical aortic valve bioprosthesis is relatively rare, not linked to short-term clinical events, and not unique to any one type of valve. Longer-term follow-up and larger studies looking specifically at this issue are warranted, experts said here at a special session devoted to the emerging understanding of the phenomenon.

HRQoL outcomes not improving for transapical TAVR

0
0
(HealthDay)—Health-related quality of life (HRQoL) outcomes have not improved for patients undergoing transapical transcatheter aortic valve replacement (TA-TAVR), according to research published online June 9 in Circulation: Cardiovascular Quality and Outcomes.

FDA: improved artificial heart valve approved

0
0
(HealthDay)—The newest version of the Sapien 3 Transcatheter Heart Valve has been approved by the U.S. Food and Drug Administration.

Cardiologists fail to identify basic and advanced murmurs

0
0
Cardiologists failed to identify more than half of basic and about 35 percent of advanced pre-recorded murmurs, but skills improved after a 90 minute training session, according to research presented today at the European Society of Cardiology Congress 2015.

Transcatheter aortic valve replacement is safe, effective for very elderly patients

0
0
Select patients age 90 years and older with aortic stenosis (AS) can benefit from a relatively new, minimally invasive surgery for aortic valve replacement, according to an article in the September 2015 issue of The Annals of Thoracic Surgery.

Blood clots may complicate aortic valve replacements

0
0
Heart valve replacements made from tissue (bioprosthetic valves) have long been thought to be spared the complication of blood clot formation. Researchers have now found that about 15 percent of all bioprosthetic aortic heart valve patients develop blood clots on the leaflets affecting valve opening, regardless of whether the patient received the new valve via open-heart surgery or a minimally-invasive catheter procedure, a new study from the Cedars-Sinai Heart Institute shows.

Favorable one-year clinical outcomes for catheter-based aortic valve replacement with latest generation of device

0
0
Penn Medicine has performed more than 1,200 Transcatheter Aortic Valve Replacements (TAVR) on patients with severe aortic stenosis. Today, at the Transcatheter Cardiac Therapeutics conference in San Francisco, Howard C. Herrmann, MD, the John Winthrop Bryfogle Professor of Cardiovascular Diseases and director of Penn Medicine's Interventional Cardiology Program in the Perelman School of Medicine at the University of Pennsylvania, will present promising findings from the PARTNER II Trial, which examined one-year clinical outcomes among high-risk or inoperable patients who received TAVR with the latest generation of balloon-expandable (SAPIEN 3) device.

Structural heart program continues to build upon minimally invasive techniques

0
0
There is a debate about when the first successful open-heart surgery was performed in the United States. Some believe it was 122 years ago in Chicago when surgeon Daniel Hale Williams performed the momentous medical advancement. The other one that lays claim to being the first was performed in Montgomery in 1902 by Luther Leonidas Hill, when he sutured a stab wound in a young boy's heart.

Mechanical heart valve prosthesis superior to biological

0
0
A mechanical valve prosthesis has a better survival record than a biological valve prosthesis, according to a large registry study from Sweden's Karolinska Institutet. The finding, which is published in the European Heart Journal, can be highly significant, since the use of biological valve prostheses has increased in all age groups in recent years.

First outcomes report from novel heart surgery registry shows excellent results for TAVR

0
0
Four years after its approval in the United States, transcatheter aortic valve replacement (TAVR) continues to evolve and demonstrate positive outcomes for patients with aortic stenosis, a common heart problem, according to a report published online by The Annals of Thoracic Surgery and the Journal of the American College of Cardiology.

Heart valves made from tissue rather than metal may be better for middle-aged patients

0
0
Patients between the ages of 40 and 70 who undergo aortic valve replacement (AVR) may fare better with tissue-based valves rather than metal-based valves, according to a review article posted online today by The Annals of Thoracic Surgery.

Heart valves in a new light

0
0
In all probability, at least one of the heart's valves – the mitral valve – functions entirely differently than previously believed. Neil Ingels, professor at the Stanford University School of Medicine, has devoted 40 years of research to the heart and its valves. Together with Matts Karlsson, professor at Linköping University, he is now putting out all the scientific data on the Internet – for Valentine's Day, suitably enough.

Women have lower mortality than men at one year after TAVR

0
0
(HealthDay)—For patients undergoing transcatheter aortic valve replacement (TAVR), women have lower mortality than men at one year, according to a study published online Feb. 23 in the Annals of Internal Medicine.

Model developed to help predict risk of in-hospital death after TAVR

0
0
In a study published online by JAMA Cardiology, Fred H. Edwards, M.D., of the University of Florida College of Medicine-Jacksonville, and colleagues developed a statistical model to predict risk of in-hospital death after transcatheter aortic valve replacement (TAVR), based on more than 13,000 patients who underwent this procedure.

Researchers find similar outcomes for patients with severe aortic stenosis who undergo transcatheter aortic valve replac

0
0
Nearly 1.5 million Americans have aortic stenosis (AS), the narrowing of the aortic valve opening which restricts blood flow to the aorta. Historically, patients have been treated with open-heart surgery, although recent research has suggested that transcatheter aortic valve replacement (TAVR) may be a better, less invasive treatment option for some high-risk patients. In this first randomized clinical trial for intermediate-risk patients with severe, symptomatic AS, conducted by researchers in the Perelman School of Medicine at the University of Pennsylvania, in partnership with Edwards Lifesciences, the Cardiovascular Research Foundation, and 56 center across the United States and Canada, investigators found that TAVR with SAPIEN XT resulted in similar two-year clinical outcomes, as compared to surgical aortic valve replacement. The study - the PARTNER II Trial - was presented today at the American College of Cardiology 65th Annual Scientific Session in Chicago and simultaneously published online in The New England Journal of Medicine.

Rates of death and stroke equivalent for surgery and TAVR at 2 years

0
0
Intermediate-risk patients with severe aortic stenosis who receive minimally invasive transcatheter aortic valve replacement, known as TAVR, have similar rates of death and disabling strokes after two years compared with those undergoing standard open heart surgical replacement, according to a study presented at the American College of Cardiology's 65th Annual Scientific Session. Patients receiving TAVR also experienced shorter hospital stays and lower incidence of some major complications compared with those undergoing surgery.
Viewing all 102 articles
Browse latest View live




Latest Images